flumazenil has been researched along with beta-Mannosidase Deficiency in 1 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Safka Brozkova, D | 1 |
Varga, L | 1 |
Uhrova Meszarosova, A | 1 |
Slobodova, Z | 1 |
Skopkova, M | 1 |
Soltysova, A | 1 |
Ficek, A | 1 |
Jencik, J | 1 |
Lastuvkova, J | 1 |
Gasperikova, D | 1 |
Seeman, P | 1 |
1 other study available for flumazenil and beta-Mannosidase Deficiency
Article | Year |
---|---|
Variant c.2158-2A>G in MANBA is an important and frequent cause of hereditary hearing loss and beta-mannosidosis among the Czech and Slovak Roma population- evidence for a new ethnic-specific variant.
Topics: beta-Mannosidosis; Czech Republic; Deafness; Ethnicity; Hearing Loss; Humans; Minority Groups; Roma; | 2020 |